The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Daneng Li
Consulting or Advisory Role - Adagene; AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Ipsen; Merck; MINA THERAPEUTICS; QED Therapeutics; Tersera
Speakers' Bureau - Coherus Biosciences; Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Adam Burgoyne
Consulting or Advisory Role - Clinical Care Options; Deciphera; Exelixis; Genentech/Roche; Kuur Therapeutics
Speakers' Bureau - AstraZeneca; Deciphera
 
Christopher Cotter
Employment - Genentech
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Shreya Badhrinarayanan
Employment - Genentech
Leadership - Genentech
Stock and Other Ownership Interests - Genentech
Travel, Accommodations, Expenses - Genentech
 
Yulei Wang
Employment - Genentech
 
Anqi Yin
Employment - Roche
 
Tirupathi Rao Edubilli
Employment - Roche
 
Edward Gane
Consulting or Advisory Role - Abbott Diagnostics; Abbvie; Aligos Therapeutics; Arbutus Biopharma; Arrowhead Pharmaceuticals; Assembly Biosciences; Avalia Immunotherapies; ClearB Therapeutics; Dicerna; Enanta; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Intellia Therapeutics; Janssen; Merck; Novartis; Vaccitech; VIR Biotechnology; Virion Therapeutics
Speakers' Bureau - Abbvie